“结核后”：在结核病治疗试验中纳入肺部健康结局的迫切需要。
"Post tuberculosis": the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials.
机构信息
St Vincent's Health Australia, Heart Lung Clinic, Sydney, Australia
University of New South Wales, Sydney, Australia.
出版信息
Eur Respir J. 2023 Sep 9;62(3). doi: 10.1183/13993003.00950-2023. Print 2023 Sep.
Abstract
摘要
相似文献
1
"Post tuberculosis": the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials.“结核后”：在结核病治疗试验中纳入肺部健康结局的迫切需要。
Eur Respir J. 2023 Sep 9;62(3). doi: 10.1183/13993003.00950-2023. Print 2023 Sep.
2
The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials.在结核病治疗临床试验中，坚持治疗的重要性及其在解释性和实用性试验中的相关性。
PLoS Med. 2019 Dec 10;16(12):e1002884. doi: 10.1371/journal.pmed.1002884. eCollection 2019 Dec.
3
Quality of tuberculosis guidelines: urgent need for improvement.结核病指南质量：亟待改进。
Int J Tuberc Lung Dis. 2010 Aug;14(8):1045-51.
4
Toward Developing a Standardized Core Set of Outcome Measures in Mobile Health Interventions for Tuberculosis Management: Systematic Review.迈向开发移动医疗干预结核病管理中标准化核心结局指标集：系统评价。
JMIR Mhealth Uhealth. 2019 Feb 19;7(2):e12385. doi: 10.2196/12385.
5
[Editorial "series on tuberculosis"].[关于结核病的社论系列]
Pneumologie. 2007 Dec;61(12):757. doi: 10.1055/s-2007-993030.
6
Tuberculosis diagnostics trials: do they lack methodological rigor?结核病诊断试验：它们是否缺乏方法学严谨性？
Expert Rev Mol Diagn. 2006 Jul;6(4):509-14. doi: 10.1586/14737159.6.4.509.
7
The China tuberculosis clinical trials consortium network: a model for international TB clinical trials capacity building.中国结核病临床试验联盟网络：国际结核病临床试验能力建设的典范。
Infect Dis Poverty. 2020 May 15;9(1):52. doi: 10.1186/s40249-020-00671-w.
8
[Characteristics of childhood tuberculosis].[儿童结核病的特征]
Pneumologie. 2009 Apr;63(4):207-18. doi: 10.1055/s-0028-1100827. Epub 2009 Mar 3.
9
Tuberculosis.结核病
Nat Rev Microbiol. 2004 Dec;2(12):930-2. doi: 10.1038/nrmicro1050.
10
Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees: Statement of the European Respiratory Society and the European Region of the International Union Against Tuberculosis and Lung Disease.呼吁采取紧急行动确保难民获得结核病的早期诊断和治疗：欧洲呼吸学会和国际防痨和肺部疾病联盟欧洲区域声明
Eur Respir J. 2016 May;47(5):1345-7. doi: 10.1183/13993003.00377-2016. Epub 2016 Mar 23.
引用本文的文献
1
A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.结核病和非结核分枝杆菌病年度回顾：2025年临床医生和科学家最新进展
Pathog Immun. 2025 Mar 2;10(2):1-45. doi: 10.20411/pai.v10i2.791. eCollection 2025.
2
The prevalence and pattern of post tuberculosis lung disease including pulmonary hypertension from an Australian TB service; a single-centre, retrospective cohort study.澳大利亚一家结核病防治机构的肺结核后疾病（包括肺动脉高压）的患病率及模式：一项单中心回顾性队列研究
BMC Pulm Med. 2025 Feb 21;25(1):84. doi: 10.1186/s12890-025-03549-5.
3
Advances in the awareness of tuberculosis-associated chronic obstructive pulmonary disease.结核病相关慢性阻塞性肺疾病认知的进展
Chin Med J Pulm Crit Care Med. 2024 Oct 18;2(4):250-256. doi: 10.1016/j.pccm.2024.08.008. eCollection 2024 Dec.
4
Post-tuberculosis lung disease: Addressing the policy gap.肺结核后肺部疾病：填补政策空白。
PLOS Glob Public Health. 2024 Sep 5;4(9):e0003560. doi: 10.1371/journal.pgph.0003560. eCollection 2024.
5
Perspectives from the 2 International Post-Tuberculosis Symposium: mobilising advocacy and research for improved outcomes.第二届国际结核病后研讨会的观点：动员宣传与研究以改善结局
IJTLD Open. 2024 Mar 1;1(3):111-123. doi: 10.5588/ijtldopen.23.0619. eCollection 2024 Mar.
6
A scoping review of interventions to address TB associated respiratory disability.一项关于应对结核病相关呼吸功能障碍干预措施的范围综述。
EClinicalMedicine. 2024 May 27;73:102646. doi: 10.1016/j.eclinm.2024.102646. eCollection 2024 Jul.
7
Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).支气管扩张症患者的气道清除管理：来自欧洲支气管扩张症注册研究（EMBARC）的数据。
Eur Respir J. 2024 Jun 6;63(6). doi: 10.1183/13993003.01689-2023. Print 2024 Jun.
本文引用的文献
1
Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14 621 people.肺结核后肺损伤：来自 14621 人的肺活量测定数据的系统评价和荟萃分析。
Eur Respir Rev. 2023 Apr 19;32(168). doi: 10.1183/16000617.0221-2022. Print 2023 Jun 30.
2
Post-TB health and wellbeing.肺结核治愈后的健康与福祉。
Int J Tuberc Lung Dis. 2023 Apr 1;27(4):248-283. doi: 10.5588/ijtld.22.0514.
3
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.24 周全口服方案治疗利福平耐药结核病。
N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166.
4
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.贝达喹啉-普托马尼德-利奈唑胺方案治疗耐药结核病。
N Engl J Med. 2022 Sep 1;387(9):810-823. doi: 10.1056/NEJMoa2119430.
5
Clinical standards for the assessment, management and rehabilitation of post-TB lung disease.肺结核后肺疾病的评估、管理和康复临床标准。
Int J Tuberc Lung Dis. 2021 Oct 1;25(10):797-813. doi: 10.5588/ijtld.21.0425.
6
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.利福喷丁四个月方案联合或不联合莫西沙星治疗结核病。
N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400.
7
Quantifying the global number of tuberculosis survivors: a modelling study.全球结核病幸存者数量的量化：一项建模研究。
Lancet Infect Dis. 2021 Jul;21(7):984-992. doi: 10.1016/S1473-3099(20)30919-1. Epub 2021 Feb 25.
8
Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge.肺结核后肺部疾病：一个被低估的全球性挑战的临床综述。
Respiration. 2021;100(8):751-763. doi: 10.1159/000512531. Epub 2021 Jan 5.
9
Beyond 'cure' and 'treatment success': quality of life of patients with multidrug-resistant tuberculosis.超越“治愈”和“治疗成功”：耐多药结核病患者的生活质量。
Int J Tuberc Lung Dis. 2019 Jan 1;23(1):73-81. doi: 10.5588/ijtld.18.0149.
Zotero 插件